Press

Press

5 Q’s for Charles Fisher, CEO of Unlearn.AI

The Center for Data Innovation spoke with Charles Fisher, chief executive officer and founder of Unlearn.AI
Press

Virtual clinical trials now being used to fast-track drug development during coronavirus crisis

Researchers, pharmaceutical companies and a handful of tech start-ups are experimenting with a new model: virtual clinical trials.
Press

8VC’s Investment in Unlearn.AI

Unlearn.AI is changing how we treat patients with medicines in trials.
Press

Will digital clones transform how pharmas run clinical trials? This S.F. startup is counting on it.

The San Francisco-based company creates digital replicas of participants in clinical drug trials using artificial intelligence.
Press

Funding Roundup: Company creating ‘digital twins’ for clinical trials raises $12M

Unlearn’s unique model has shown that it can provide realistic digital patient records to supplement actual control patients in Alzheimer’s Disease trials
Press

Unlearn.AI Gets $12 Million to Give Digital Boost to Human Clinical Studies

Unlearn.AI Inc. has raised $12 million to pursue a goal of using artificial intelligence to help life sciences companies run better clinical trials...
Press

Unlearn Adds $12M for “Digital Twins” That Accelerate Clinical Trials

Unlearn has built disease-specific models that generate control patient data by using demographic information and observations of the same variables over time, such as common lab tests and...
Press

Unlearn.AI Closes On $12M To Improve Clinical Trials

The Unlearn platform processes historical clinical trial datasets from thousands of patients to build the disease-specific machine-learning models used to create what is called “Digital Twins” and...
Press

Unlearn.AI nabs $12M to build “Digital Twins” to speed up and improve clinical trials

“Unlearn’s pioneering use of Digital Twins will limit the number of patients that need to go on placebo while also reducing overall trial enrollment time."
Press

Unlearn.AI Closes $12M Series A to Advance the Use of Digital Twins in Clinical Trials

“This new financing marks an important milestone in our growth and will contribute to the significant progress we are making with regulators and with our commercial partners, who are already...
Press

CTAD Lessons for 2020: More Phase 2 Trials, More Diversity

Smith and colleagues used 18 months of data on 1,909 patients from the Coalition Against Major Diseases (CAMD) AD database to develop an algorithm for generating digital twins.
Press

230 Startups Using Artificial Intelligence in Drug Discovery

Unlearn.AI allows researchers to: Populate control arms in clinical trials, enabling rigorous clinical evidence with fewer subjects.
Press

AI, machine learning offer hope for speeding Alzheimer's development

Machine learning and artificial intelligence (AI) are already being actively used in drug discovery to evaluate potential binding of small-molecule drugs to proteins, but there's potential for the...
Press

Unlearn.AI Announces Results Generated from First-of-its-Kind Machine Learning Platform to Accelerate Alzheimer's Drug Development

Technology creates Digital Twins and Intelligent Control Arms to reduce clinical trial timelines and improve confidence in trial results
Press

Digital Twin Advances Poised to Expand Clinical Trial Reach

Digital twins enable faster recruitment with higher powered, individualized trials [capable of generating] additional data from the same or fewer number of patients.
Press

The FDA needs to set standards for using artificial intelligence in drug development

Clinical trials could be made more efficient by using artificial intelligence to incorporate other data sources, such as historical control arms or real-world data.
Press

Broadening Role for External Control Arms in Clinical Trials

Unlearn.AI Inc. is going a step further, using data from historical trials and patient registries to build algorithms that simulate artificial patients.
Press

Researcher use AI to predict Alzheimer's disease progression

“Understanding how to predict and manage differences between patients is the primary goal of precision medicine. Computational models of disease progression developed using machine learning...